CSPC Pharmaceutical Group Limited
Shiyao Group Co., Ltd. was founded in May 1938. It is one of the earliest pharmaceutical companies established by our party and army. It has made great contributions to the victory of the War of Resistance Against Japan, the War of Liberation, and the medical and health care cause of the socialist New China. Shiyao Group has a total assets of 15 billion yuan and more than 20,000 employees. It is the first super-large pharmaceutical enterprise established in the pharmaceutical industry in the country through a strong joint method, and is also one of the large-scale pillar enterprise groups in Hebei Province. Shi Pharmaceutical Group has six major business segments, and more than 30 subsidiaries including Zhongrun Pharmaceutical, Weisheng Pharmaceutical, Zhongnuo Pharmaceutical, Ouyi Pharmaceutical, Enbipu Pharmaceutical, Yinhu Pharmaceutical, etc., are located in Hebei, Tianjin, Ji, Jin, Liao, Shandong, Inner Mongolia and Hong Kong. Among them, the holding subsidiary located in Hong Kong, China Pharmaceutical Group Co., Ltd. is the first overseas listed company in the Chinese pharmaceutical industry. It is currently one of the largest pharmaceutical listed companies in Hong Kong and one of the constituent stocks of the Hong Kong Hang Seng Red Chip Stock Index. It has been rated as one of the 100 outstanding listed companies with a turnover of less than US$1 billion by the world-renowned Forbes magazine for two consecutive times. Shiyao Group is mainly engaged in the development, production and sales of pharmaceutical products. The products mainly include nearly a thousand varieties, including seven series, including antibiotics, vitamins, cardiovascular and cerebrovascular, antipyretic and analgesic, digestive system medication, respiratory system medication and Chinese patent medicine. At present, the annual production capacity of eight products including vitamin C, penicillin, amoxicillin, caffeine, 7-ACA ranks first in the world. The annual production capacity of Shiyao Group's preparation products is 3 billion powder injections, 20 billion tablets, 8 billion capsules, and 1 billion soft capsules. The output, scale and strength of the leading products of Shiyao Group rank among the best in the country, and has developed into one of China's largest "chemical raw materials production base" and "comprehensive preparation production base". Currently, Shiyao Group has 30 products with single products sold over 100 million yuan, and its product sales are spread across the country and more than 60 countries and regions in the world. Over the past ten years since its establishment, Shijiao Group has been continuously pioneering and innovating with the strong support of all sectors of society, and has achieved continuous, healthy and rapid development, and has achieved gratifying results. The company's comprehensive strength has always been at the forefront of the Chinese pharmaceutical industry. It has successively won honorary titles such as the National Medical System Advanced Collective, Quality-Efficient Advanced Enterprise, Product Quality Relief Commitment Unit, National May 1st Labor Certificate, China Environmental Protection Enterprise Charity Award and other honorary titles. In 2010, the group's sales revenue reached 13.088 billion yuan, a year-on-year increase of 23%, ranking second among pharmaceutical industry enterprises in the country for four consecutive years; achieved profits and taxes of 1.605 billion yuan, a year-on-year increase of 10.22%; paid 730 million yuan of various taxes; exports earned US$550 million, a year-on-year increase of 22%, and the total export volume continued to rank first in the domestic pharmaceutical industry. In terms of scientific research and development, Shijiao Group relies on the company's "postdoctoral research workstation", national enterprise technology center, "863 Plan" high-tech industrialization base and Hebei Provincial Preparation Engineering Technology Center, and has successively developed and developed new drugs in more than 110 national areas in recent years, involving biotechnology, chiral synthetic drugs, liposomes, transdermal preparations, molecular microcapsules and other fields. At present, Shiyao Group has applied for more than 220 patents, 116 have been authorized, 17 PCT international patents have been applied for, and has obtained authorization in 18 countries. Among them, the first-class new drug "Embipu" in the country with independent intellectual property rights is a global leading drug in the field of stroke treatment. It is the third national new drug in my country with independent intellectual property rights. It is protected by patents in 86 countries around the world. At present, the company has signed a patent use rights transfer agreement for Enbipu Soft Capsules in the European and American and Korean markets with two well-known companies, the United States and South Korea, setting a precedent for Chinese pharmaceutical companies to transfer drug intellectual property rights to the world's most developed countries, and won honors for the country and nation. In 2008, under the leadership of the Ministry of Science and Technology, the China Antibiotic Industry Technology Innovation Alliance was led by the establishment of the China Antibiotic Industry Technology Support Alliance and obtained project support from the National Science and Technology Support Plan. In the application for the national major science and technology project of "Major New Drug Creation", 1 innovative drug incubation base, 3 innovative drug research and development technology platforms and 6 new drug development projects have settled in Shiyao. In 2009, the Group's pharmaceutical preparation and drug release technology laboratory ranked among the "National Key Laboratory", and the "Butyphthalide Raw Materials and Soft Capsules" project won the second prize of the National Science and Technology Progress Award. The Group was jointly rated as a "National Innovation Enterprise" by the Ministry of Science and Technology, the State-owned Assets Supervision and Administration Commission of the State Council, and the All-China Federation of Trade Unions, marking that the Group's innovation system has entered a new stage of systematization and institutionalization. In terms of product quality, Shijiao Group has established a complete three-level quality management system. All drugs have passed GMP certification, and all subordinate enterprises have passed ISO9000, OHSAS18000 and ISO14001 certifications. The product market inspection pass rate has always remained 100%. At the same time, the company uses technology to improve its quality connotation. Currently, 11 raw material products such as caffeine, vitamin C, vitamin B12, and amoxicillin have obtained EU COS certification. In May 2010, the group's oral solid preparation workshop, vitamin C and sodium vitamin C passed the US FDA certification with the highest quality standards in the world with "zero defects". It is the first domestic preparation manufacturer to pass the FDA certification using domestic equipment, and it is also the first company in Asia to produce online FDA certification, and has obtained a "pass" to enter the high-end pharmaceutical market in Europe and the United States. In terms of brand building, Shiyao Group owns two "famous Chinese trademarks: "Shiyao" and "Ouyi"; after being evaluated by the World Brand Laboratory, one of the world's five major brand value evaluation institutions, the "Shiyao" brand has been selected as the "China's 500 Most Valuable Brands" for four consecutive years since 2005, and Shiyao Group has ranked among the top 500 Chinese companies for three consecutive times. In terms of fulfilling social responsibilities, Shiyao Group is always at the forefront and always enthusiastically supports social welfare undertakings. Shiyao is always indispensable in activities such as SARS, Indonesian tsunami, Wenchuan earthquake, Yushu earthquake, medical care for children with serious illnesses, volunteer services, and visits to old areas. Shiyao Group has been constantly giving back to the society with real things. Since its establishment, it has invested more than 60 million yuan in public welfare undertakings. Looking forward to the future, Shiyao People will continue to uphold the corporate philosophy of "making good medicines for China", be committed to the cause of human health, contribute to the society with more, newer and better drugs, and strive to build Shiyao Group into a top-class domestic and top 30 pharmaceutical companies in the world.
CSPC Pharmaceutical Group Limited
Shiyao Group Co., Ltd. was founded in May 1938. It is one of the earliest pharmaceutical companies established by our party and army. It has made great contributions to the victory of the War of Resistance Against Japan, the War of Liberation, and the medical and health care cause of the socialist New China. Shiyao Group has a total assets of 15 billion yuan and more than 20,000 employees. It is the first super-large pharmaceutical enterprise established in the pharmaceutical industry in the country through a strong joint method, and is also one of the large-scale pillar enterprise groups in Hebei Province. Shi Pharmaceutical Group has six major business segments, and more than 30 subsidiaries including Zhongrun Pharmaceutical, Weisheng Pharmaceutical, Zhongnuo Pharmaceutical, Ouyi Pharmaceutical, Enbipu Pharmaceutical, Yinhu Pharmaceutical, etc., are located in Hebei, Tianjin, Ji, Jin, Liao, Shandong, Inner Mongolia and Hong Kong. Among them, the holding subsidiary located in Hong Kong, China Pharmaceutical Group Co., Ltd. is the first overseas listed company in the Chinese pharmaceutical industry. It is currently one of the largest pharmaceutical listed companies in Hong Kong and one of the constituent stocks of the Hong Kong Hang Seng Red Chip Stock Index. It has been rated as one of the 100 outstanding listed companies with a turnover of less than US$1 billion by the world-renowned Forbes magazine for two consecutive times. Shiyao Group is mainly engaged in the development, production and sales of pharmaceutical products. The products mainly include nearly a thousand varieties, including seven series, including antibiotics, vitamins, cardiovascular and cerebrovascular, antipyretic and analgesic, digestive system medication, respiratory system medication and Chinese patent medicine. At present, the annual production capacity of eight products including vitamin C, penicillin, amoxicillin, caffeine, 7-ACA ranks first in the world. The annual production capacity of Shiyao Group's preparation products is 3 billion powder injections, 20 billion tablets, 8 billion capsules, and 1 billion soft capsules. The output, scale and strength of the leading products of Shiyao Group rank among the best in the country, and has developed into one of China's largest "chemical raw materials production base" and "comprehensive preparation production base". Currently, Shiyao Group has 30 products with single products sold over 100 million yuan, and its product sales are spread across the country and more than 60 countries and regions in the world. Over the past ten years since its establishment, Shijiao Group has been continuously pioneering and innovating with the strong support of all sectors of society, and has achieved continuous, healthy and rapid development, and has achieved gratifying results. The company's comprehensive strength has always been at the forefront of the Chinese pharmaceutical industry. It has successively won honorary titles such as the National Medical System Advanced Collective, Quality-Efficient Advanced Enterprise, Product Quality Relief Commitment Unit, National May 1st Labor Certificate, China Environmental Protection Enterprise Charity Award and other honorary titles. In 2010, the group's sales revenue reached 13.088 billion yuan, a year-on-year increase of 23%, ranking second among pharmaceutical industry enterprises in the country for four consecutive years; achieved profits and taxes of 1.605 billion yuan, a year-on-year increase of 10.22%; paid 730 million yuan of various taxes; exports earned US$550 million, a year-on-year increase of 22%, and the total export volume continued to rank first in the domestic pharmaceutical industry. In terms of scientific research and development, Shijiao Group relies on the company's "postdoctoral research workstation", national enterprise technology center, "863 Plan" high-tech industrialization base and Hebei Provincial Preparation Engineering Technology Center, and has successively developed and developed new drugs in more than 110 national areas in recent years, involving biotechnology, chiral synthetic drugs, liposomes, transdermal preparations, molecular microcapsules and other fields. At present, Shiyao Group has applied for more than 220 patents, 116 have been authorized, 17 PCT international patents have been applied for, and has obtained authorization in 18 countries. Among them, the first-class new drug "Embipu" in the country with independent intellectual property rights is a global leading drug in the field of stroke treatment. It is the third national new drug in my country with independent intellectual property rights. It is protected by patents in 86 countries around the world. At present, the company has signed a patent use rights transfer agreement for Enbipu Soft Capsules in the European and American and Korean markets with two well-known companies, the United States and South Korea, setting a precedent for Chinese pharmaceutical companies to transfer drug intellectual property rights to the world's most developed countries, and won honors for the country and nation. In 2008, under the leadership of the Ministry of Science and Technology, the China Antibiotic Industry Technology Innovation Alliance was led by the establishment of the China Antibiotic Industry Technology Support Alliance and obtained project support from the National Science and Technology Support Plan. In the application for the national major science and technology project of "Major New Drug Creation", 1 innovative drug incubation base, 3 innovative drug research and development technology platforms and 6 new drug development projects have settled in Shiyao. In 2009, the Group's pharmaceutical preparation and drug release technology laboratory ranked among the "National Key Laboratory", and the "Butyphthalide Raw Materials and Soft Capsules" project won the second prize of the National Science and Technology Progress Award. The Group was jointly rated as a "National Innovation Enterprise" by the Ministry of Science and Technology, the State-owned Assets Supervision and Administration Commission of the State Council, and the All-China Federation of Trade Unions, marking that the Group's innovation system has entered a new stage of systematization and institutionalization. In terms of product quality, Shijiao Group has established a complete three-level quality management system. All drugs have passed GMP certification, and all subordinate enterprises have passed ISO9000, OHSAS18000 and ISO14001 certifications. The product market inspection pass rate has always remained 100%. At the same time, the company uses technology to improve its quality connotation. Currently, 11 raw material products such as caffeine, vitamin C, vitamin B12, and amoxicillin have obtained EU COS certification. In May 2010, the group's oral solid preparation workshop, vitamin C and sodium vitamin C passed the US FDA certification with the highest quality standards in the world with "zero defects". It is the first domestic preparation manufacturer to pass the FDA certification using domestic equipment, and it is also the first company in Asia to produce online FDA certification, and has obtained a "pass" to enter the high-end pharmaceutical market in Europe and the United States. In terms of brand building, Shiyao Group owns two "famous Chinese trademarks: "Shiyao" and "Ouyi"; after being evaluated by the World Brand Laboratory, one of the world's five major brand value evaluation institutions, the "Shiyao" brand has been selected as the "China's 500 Most Valuable Brands" for four consecutive years since 2005, and Shiyao Group has ranked among the top 500 Chinese companies for three consecutive times. In terms of fulfilling social responsibilities, Shiyao Group is always at the forefront and always enthusiastically supports social welfare undertakings. Shiyao is always indispensable in activities such as SARS, Indonesian tsunami, Wenchuan earthquake, Yushu earthquake, medical care for children with serious illnesses, volunteer services, and visits to old areas. Shiyao Group has been constantly giving back to the society with real things. Since its establishment, it has invested more than 60 million yuan in public welfare undertakings. Looking forward to the future, Shiyao People will continue to uphold the corporate philosophy of "making good medicines for China", be committed to the cause of human health, contribute to the society with more, newer and better drugs, and strive to build Shiyao Group into a top-class domestic and top 30 pharmaceutical companies in the world.
Shanghai Pharmaceutical Holding Co., Ltd.
Shanghai Pharmaceutical Group Co., Ltd., a national pharmaceutical industry group, a national enterprise technology center, and a top 500 Chinese enterprises. It ranks among the top in the national pharmaceutical retail industry. It is a listed company, a comprehensive pharmaceutical enterprise in the entire industry chain integrating pharmaceutical research and development, manufacturing, distribution and retail. Shanghai Pharmaceutical Group Co., Ltd. is the only pharmaceutical listed company in China that has a leading position in pharmaceutical products and distribution markets. The company's R&D is based on innovation as its long-term adherence to, and is committed to providing safe and effective therapeutic drugs for major diseases and chronic diseases. In 2012, R&D investment accounted for 4.72% of the company's pharmaceutical business sales revenue. The company has established a research and development system for the branch of the Group General Academy with the Central Research Institute as its technical core, with 1 national-level enterprise technology center and 10 provincial and municipal enterprise technology centers, and has been selected for more than ten major national science and technology projects of "major new drug creation". The company adopts an open research model, established a strategic alliance for innovative drug research and development with the Shanghai Institute of Pharmaceuticals of the Chinese Academy of Sciences, established joint laboratories with China Pharmaceutical University, Shenyang Pharmaceutical University, etc., and cooperated with Japan's Mitsubishi Tanabe Pharmaceutical Co., Ltd. and Shanghai Fudan Zhangjiang Biomedicine to carry out innovative drug research and development; at the same time, it also began to enter the field of therapeutic antibodies through project introduction, cooperative development and other methods. Shanghai pharmaceutical manufacturing covers the fields of chemical and biological medicine, modern Chinese medicine and health products, medical devices, etc. The products focus on five major therapeutic areas: cardiovascular and cerebrovascular, systemic anti-infection, digestive system and immunometabolism, neuropsychiatric, and anti-tumor. It produces more than 20 dosage forms such as tablets, capsules, powder injections (including lyophilized), small-volume injections, eye drops, aerosols, gels, etc., and has over 100 million products. The company's Xinyi, Leishi, Longhu, Qingchunbao, Hu Qingyutang, Cangsong, Guofeng, Shenxiang and other brands are well-known trademarks in China. The company's pharmaceutical production strictly implements China's new version of GMP requirements, and multiple raw materials or preparations have passed the quality certification of WHO, FDA, the EU and other developed countries. Shanghai Pharmaceutical's distribution network radiates across the country with the three key areas of East China, North China and South China, with the most economically developed in China, and ranks second in the country in terms of business scale. The company's distribution business is mainly hospital pure sales, and it cooperates with more than 40 multinational pharmaceutical companies around the world. The company's new businesses such as vaccines, high-end consumables, DTP (direct delivery of high-value drugs) and SPD (pharmaceutical flow management technology) are leading in China. The company's distribution services are gradually moving towards modern hospital service solutions with supply chain extension services and clinical support services as the core, providing hospital customers with terminal solutions, special logistics and information services. Shanghai Pharmaceutical Retail has many well-known brands such as Fahrenheit, Lei Yunshang, Yu Tiancheng, Life Insurance, Leimon, Keyuan Xinhai Pharmacy, etc., covering 12 provinces, municipalities and autonomous regions across the country, with a total of 1,792 stores. In 2012, the company's pharmaceutical retail sales scale ranked among the top five in the national pharmaceutical retail industry, and Shanghai Fahrenheit Pharmacy is the company with the largest number of pharmacies in East China. Shanghai Pharmaceutical's retail business includes chain pharmacies, co-organized pharmacies, DTP pharmacies and other business formats, and actively develops e-commerce to achieve online sales. Shanghai Pharmaceutical advocates the core corporate values of "innovation, integrity, cooperation, inclusiveness, and responsibility", and is committed to perseverance, improving the people's healthy quality of life, and striving to build a leading brand drug manufacturer and health service provider that is respected and has an industry reputation.
Shanghai Pharmaceutical Holding Co., Ltd.
Shanghai Pharmaceutical Group Co., Ltd., a national pharmaceutical industry group, a national enterprise technology center, and a top 500 Chinese enterprises. It ranks among the top in the national pharmaceutical retail industry. It is a listed company, a comprehensive pharmaceutical enterprise in the entire industry chain integrating pharmaceutical research and development, manufacturing, distribution and retail. Shanghai Pharmaceutical Group Co., Ltd. is the only pharmaceutical listed company in China that has a leading position in pharmaceutical products and distribution markets. The company's R&D is based on innovation as its long-term adherence to, and is committed to providing safe and effective therapeutic drugs for major diseases and chronic diseases. In 2012, R&D investment accounted for 4.72% of the company's pharmaceutical business sales revenue. The company has established a research and development system for the branch of the Group General Academy with the Central Research Institute as its technical core, with 1 national-level enterprise technology center and 10 provincial and municipal enterprise technology centers, and has been selected for more than ten major national science and technology projects of "major new drug creation". The company adopts an open research model, established a strategic alliance for innovative drug research and development with the Shanghai Institute of Pharmaceuticals of the Chinese Academy of Sciences, established joint laboratories with China Pharmaceutical University, Shenyang Pharmaceutical University, etc., and cooperated with Japan's Mitsubishi Tanabe Pharmaceutical Co., Ltd. and Shanghai Fudan Zhangjiang Biomedicine to carry out innovative drug research and development; at the same time, it also began to enter the field of therapeutic antibodies through project introduction, cooperative development and other methods. Shanghai pharmaceutical manufacturing covers the fields of chemical and biological medicine, modern Chinese medicine and health products, medical devices, etc. The products focus on five major therapeutic areas: cardiovascular and cerebrovascular, systemic anti-infection, digestive system and immunometabolism, neuropsychiatric, and anti-tumor. It produces more than 20 dosage forms such as tablets, capsules, powder injections (including lyophilized), small-volume injections, eye drops, aerosols, gels, etc., and has over 100 million products. The company's Xinyi, Leishi, Longhu, Qingchunbao, Hu Qingyutang, Cangsong, Guofeng, Shenxiang and other brands are well-known trademarks in China. The company's pharmaceutical production strictly implements China's new version of GMP requirements, and multiple raw materials or preparations have passed the quality certification of WHO, FDA, the EU and other developed countries. Shanghai Pharmaceutical's distribution network radiates across the country with the three key areas of East China, North China and South China, with the most economically developed in China, and ranks second in the country in terms of business scale. The company's distribution business is mainly hospital pure sales, and it cooperates with more than 40 multinational pharmaceutical companies around the world. The company's new businesses such as vaccines, high-end consumables, DTP (direct delivery of high-value drugs) and SPD (pharmaceutical flow management technology) are leading in China. The company's distribution services are gradually moving towards modern hospital service solutions with supply chain extension services and clinical support services as the core, providing hospital customers with terminal solutions, special logistics and information services. Shanghai Pharmaceutical Retail has many well-known brands such as Fahrenheit, Lei Yunshang, Yu Tiancheng, Life Insurance, Leimon, Keyuan Xinhai Pharmacy, etc., covering 12 provinces, municipalities and autonomous regions across the country, with a total of 1,792 stores. In 2012, the company's pharmaceutical retail sales scale ranked among the top five in the national pharmaceutical retail industry, and Shanghai Fahrenheit Pharmacy is the company with the largest number of pharmacies in East China. Shanghai Pharmaceutical's retail business includes chain pharmacies, co-organized pharmacies, DTP pharmacies and other business formats, and actively develops e-commerce to achieve online sales. Shanghai Pharmaceutical advocates the core corporate values of "innovation, integrity, cooperation, inclusiveness, and responsibility", and is committed to perseverance, improving the people's healthy quality of life, and striving to build a leading brand drug manufacturer and health service provider that is respected and has an industry reputation.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Zhengda Tianqing Pharmaceutical Group Co., Ltd. was founded in 1997. It is a high-tech enterprise, a large domestic liver health drug research and development and production base, and a large pharmaceutical enterprise integrating scientific research, production and sales. Zhengda Tianqing Pharmaceutical Group is an innovative pharmaceutical group enterprise integrating scientific research, production and sales, and is a domestic liver health drug research and development and production base. Zhengda Tianqing has always regarded scientific and technological innovation as an important strategy for corporate development and is one of the pharmaceutical companies that have invested a lot in innovative drug research in China. With the development of enterprises and the improvement of R&D capabilities, Zhengda Tianqing's R&D expenses have exceeded 1 billion yuan per year, and will gradually follow multinational companies. At present, the institute has 247 projects under development, including 31 new drugs in Class I and 32 biological drugs. Zhengda Tianqing has built three production bases in Lianyungang, covering a total area of more than 800 mu, including an incubation base covering an area of 160 mu, a raw material medicine base covering an area of more than 200 mu, and a preparation base covering an area of 480 mu. The Zhengda Tianqing Preparation Base is designed and built in accordance with the EU and US FDA standards. Small-capacity injections have obtained the first GMP certificate in the country, and oral solid preparations have obtained the first GMP certificate in Jiangsu Province. In June 2014, the preparation base passed the EU certification and obtained the EU-recognized GMP certification certificate issued by the German Drug Administration. At present, Zhengda Tianqing is preparing for the four major flagship products to enter the international market. In the future, these drugs will become a new weapon for Zhengda Tianqing to open the international market. The treatment field of Zhengda Tianqing’s product involves various diseases such as liver disease, tumors, respiratory, infection, digestion, etc. 14 products with annual sales of over 100 million yuan have formed a "billion yuan product group", including two products with annual sales of over 2 billion yuan, namely the national first-class new drug isoglycidyl injection (Tianqing Ganmei) and the early domestic entecavir dispersed tablets (Runzhong). In addition to the field of strong liver disease, the anti-tumor field has also formed a unique product line. The hematologic tumor products decitabine, imatinib and dasatinib are the first domestic imitation; the solid tumor product capecitabine has been approved for marketing. Respiratory, antibiotics, endocrine and other fields will also be the direction of future development of enterprises. In the future development, Zhengda Tianqing Pharmaceutical will continue to strengthen the construction of core competitiveness, establish and improve a scientific R&D system, so that the company's R&D level will always be in line with the international frontier.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Zhengda Tianqing Pharmaceutical Group Co., Ltd. was founded in 1997. It is a high-tech enterprise, a large domestic liver health drug research and development and production base, and a large pharmaceutical enterprise integrating scientific research, production and sales. Zhengda Tianqing Pharmaceutical Group is an innovative pharmaceutical group enterprise integrating scientific research, production and sales, and is a domestic liver health drug research and development and production base. Zhengda Tianqing has always regarded scientific and technological innovation as an important strategy for corporate development and is one of the pharmaceutical companies that have invested a lot in innovative drug research in China. With the development of enterprises and the improvement of R&D capabilities, Zhengda Tianqing's R&D expenses have exceeded 1 billion yuan per year, and will gradually follow multinational companies. At present, the institute has 247 projects under development, including 31 new drugs in Class I and 32 biological drugs. Zhengda Tianqing has built three production bases in Lianyungang, covering a total area of more than 800 mu, including an incubation base covering an area of 160 mu, a raw material medicine base covering an area of more than 200 mu, and a preparation base covering an area of 480 mu. The Zhengda Tianqing Preparation Base is designed and built in accordance with the EU and US FDA standards. Small-capacity injections have obtained the first GMP certificate in the country, and oral solid preparations have obtained the first GMP certificate in Jiangsu Province. In June 2014, the preparation base passed the EU certification and obtained the EU-recognized GMP certification certificate issued by the German Drug Administration. At present, Zhengda Tianqing is preparing for the four major flagship products to enter the international market. In the future, these drugs will become a new weapon for Zhengda Tianqing to open the international market. The treatment field of Zhengda Tianqing’s product involves various diseases such as liver disease, tumors, respiratory, infection, digestion, etc. 14 products with annual sales of over 100 million yuan have formed a "billion yuan product group", including two products with annual sales of over 2 billion yuan, namely the national first-class new drug isoglycidyl injection (Tianqing Ganmei) and the early domestic entecavir dispersed tablets (Runzhong). In addition to the field of strong liver disease, the anti-tumor field has also formed a unique product line. The hematologic tumor products decitabine, imatinib and dasatinib are the first domestic imitation; the solid tumor product capecitabine has been approved for marketing. Respiratory, antibiotics, endocrine and other fields will also be the direction of future development of enterprises. In the future development, Zhengda Tianqing Pharmaceutical will continue to strengthen the construction of core competitiveness, establish and improve a scientific R&D system, so that the company's R&D level will always be in line with the international frontier.
Beijing Tongrentang (Group) Co., Ltd.
China Beijing Tongrentang (Group) Co., Ltd. is a wholly state-owned company authorized by the municipal government to operate state-owned assets. Tongrentang was founded in 1669 and has a history of more than 300 years. Beijing Tongrentang has always adhered to the development strategy of "taking modern Chinese medicine as the core, developing life and health industries, and becoming an internationally renowned modern Chinese medicine group", taking the policy of "longer, stronger, and bigger", leading with innovation and developing enterprises with technology As its own mission, it has formed three major sectors: modern pharmaceutical industry, retail commerce and medical services, and has built an enterprise structure of six secondary groups, three hospitals and two reserve units. It currently has three listed companies. The group has more than 1,500 products including medicines, hospital preparations, health foods, foods, cosmetics, etc., 28 production bases, 83 modern production lines, a national engineering center and a postdoctoral research workstation. Since 1997, Tongrentang has maintained sustained and healthy development, and its economic indicators have maintained double-digit growth for 15 consecutive years, doubling every five years. As of 2011, the group had a total assets of 14 billion yuan, sales revenue of 16.3 billion yuan, profit of 1.316 billion yuan, export revenue of 33.92 million US dollars, and opened 64 pharmacies and 1 overseas production and R&D base in 16 overseas countries and regions. Products Sales to more than 40 countries and regions overseas. With the rapid development of Tongrentang, the brand maintenance and improvement, the innovation and inheritance of culture have also achieved fruitful results. "Tongrentang Traditional Chinese Medicine Culture" has been included in the first batch of national intangible cultural heritage list. Tongrentang is both an economic entity and a culture. The dual functions of carriers are becoming increasingly apparent.
Beijing Tongrentang (Group) Co., Ltd.
China Beijing Tongrentang (Group) Co., Ltd. is a wholly state-owned company authorized by the municipal government to operate state-owned assets. Tongrentang was founded in 1669 and has a history of more than 300 years. Beijing Tongrentang has always adhered to the development strategy of "taking modern Chinese medicine as the core, developing life and health industries, and becoming an internationally renowned modern Chinese medicine group", taking the policy of "longer, stronger, and bigger", leading with innovation and developing enterprises with technology As its own mission, it has formed three major sectors: modern pharmaceutical industry, retail commerce and medical services, and has built an enterprise structure of six secondary groups, three hospitals and two reserve units. It currently has three listed companies. The group has more than 1,500 products including medicines, hospital preparations, health foods, foods, cosmetics, etc., 28 production bases, 83 modern production lines, a national engineering center and a postdoctoral research workstation. Since 1997, Tongrentang has maintained sustained and healthy development, and its economic indicators have maintained double-digit growth for 15 consecutive years, doubling every five years. As of 2011, the group had a total assets of 14 billion yuan, sales revenue of 16.3 billion yuan, profit of 1.316 billion yuan, export revenue of 33.92 million US dollars, and opened 64 pharmacies and 1 overseas production and R&D base in 16 overseas countries and regions. Products Sales to more than 40 countries and regions overseas. With the rapid development of Tongrentang, the brand maintenance and improvement, the innovation and inheritance of culture have also achieved fruitful results. "Tongrentang Traditional Chinese Medicine Culture" has been included in the first batch of national intangible cultural heritage list. Tongrentang is both an economic entity and a culture. The dual functions of carriers are becoming increasingly apparent.
Jilin Aodong Pharmaceutical Group Co., Ltd.
The predecessor of Jilin Aodong Pharmaceutical Group Co., Ltd. was the state-owned Yanbian Dunhua Luchang established in 1957. Aodong Pharmaceutical Factory was established in 1981. In March 1993, it was reorganized into Jilin Aodong Pharmaceutical Group Co., Ltd. with the approval of the Provincial Sports Reform Commission. The company was listed on the Shenzhen Stock Exchange on October 28, 1996. The company currently holds 7 professional pharmaceutical subsidiaries engaged in modern Chinese medicine, biochemical drugs and phytochemical drugs, 1 pharmaceutical sales subsidiary, 2 pharmaceutical supporting subsidiaries and shares in GF Securities and Tadong Mining, and has planting and breeding bases. Established an industrial chain operation model of "company + standardized base + franchised farmers" and gradually developed into a holding group integrating "resource sharing, scientific management, and sustainable development" that integrates the pharmaceutical industry, securities industry, mining industry and highway construction industry. company. The company's registered address is No. 2158 Aodong Street, Dunhua City, Jilin Province. The company's total share capital is 573.35797 million shares, and the legal representative is Li Xiulin. As of the end of 2009, the company's total assets were RMB 7162.21 million, its net assets were RMB 6560.37 million, and its debt-to-asset ratio was 8.40%. In 2009, the sales revenue was RMB 1025.52 million, the total profit was RMB 1413.13 million, and the net profit was RMB 1366.49 million. In 1998, the company was recognized as a national technology center by the State Economic and Trade Commission and became the main technical support for enterprise technological progress and technological innovation. On December 11, 2001, the Ministry of Personnel approved the establishment of a postdoctoral workstation. During the 11th Five-Year Plan period, Jilin Aodong National Technology Center was built into a new technology research and development center, an industry-university-research cooperation and exchange center, and a technical decision-making consulting center; in 2002, the company Approved by the Ministry of Agriculture and nine other ministries and commissions as a national key leading enterprise in agricultural industrialization; in September 2003, it was rated as an "Excellent High-tech Enterprise in the Torch Program" by the Ministry of Science and Technology; in January 2002, it was rated as a demonstration enterprise for the modern science and technology industry base of traditional Chinese medicine ;In April 2007, he won the National May 1st Labor Certificate and was once again rated as a leading enterprise in agricultural industrialization by the Ministry of Agriculture and nine other ministries and commissions; in January 2008, he was rated as a demonstration unit for enterprise informationization in Jilin Province, and won the Jilin Province A for many years Taxpayer enterprise, AAA bank credit rating, contract-abiding and credit-oriented unit, etc.; in December 2009, he won the 16th National First-Class Enterprise Management Modernization Innovation Achievements. After decades of development, the company has formed a unique brand advantage. The "Aodong and Tu" trademark was recognized as a well-known protection by the State Administration for Industry and Commerce in 1999, and has become the "China's 500 Most Valuable Brand" for six consecutive years. The company's leading products "Anshen Bu Brain Liquid", "Xuefu Zhuyu Oral Liquid", "Li Naoxin Capsules", and "Xin Nao Shutong Capsules" have maintained the titles of provincial, ministry and famous Chinese traditional Chinese medicine products for many years. "Calf spleen extract injection", "Riben nucleic acid II for injection", "Lufei granules", "Shaofu Zhuyu granules", "Yangxueyin oral liquid", "Yuxindou Capsule", "Children Chai Gui Products such as oral liquid have also been well received by the market for their stable quality and efficacy. The sales volume has increased year by year, laying a solid foundation for the company's sustainable development. The company will continue to thoroughly implement the policy of "strengthening fine production management, deepening marketing system reform, adjusting product research and development direction, promoting information network construction, improving business target assessment, and enhancing the comprehensive strength of the enterprise", create greater value for shareholders, and take into account consumption. The interests of those who are involved in the social and economic development and other related parties will contribute to the development of the society and economy.
Jilin Aodong Pharmaceutical Group Co., Ltd.
The predecessor of Jilin Aodong Pharmaceutical Group Co., Ltd. was the state-owned Yanbian Dunhua Luchang established in 1957. Aodong Pharmaceutical Factory was established in 1981. In March 1993, it was reorganized into Jilin Aodong Pharmaceutical Group Co., Ltd. with the approval of the Provincial Sports Reform Commission. The company was listed on the Shenzhen Stock Exchange on October 28, 1996. The company currently holds 7 professional pharmaceutical subsidiaries engaged in modern Chinese medicine, biochemical drugs and phytochemical drugs, 1 pharmaceutical sales subsidiary, 2 pharmaceutical supporting subsidiaries and shares in GF Securities and Tadong Mining, and has planting and breeding bases. Established an industrial chain operation model of "company + standardized base + franchised farmers" and gradually developed into a holding group integrating "resource sharing, scientific management, and sustainable development" that integrates the pharmaceutical industry, securities industry, mining industry and highway construction industry. company. The company's registered address is No. 2158 Aodong Street, Dunhua City, Jilin Province. The company's total share capital is 573.35797 million shares, and the legal representative is Li Xiulin. As of the end of 2009, the company's total assets were RMB 7162.21 million, its net assets were RMB 6560.37 million, and its debt-to-asset ratio was 8.40%. In 2009, the sales revenue was RMB 1025.52 million, the total profit was RMB 1413.13 million, and the net profit was RMB 1366.49 million. In 1998, the company was recognized as a national technology center by the State Economic and Trade Commission and became the main technical support for enterprise technological progress and technological innovation. On December 11, 2001, the Ministry of Personnel approved the establishment of a postdoctoral workstation. During the 11th Five-Year Plan period, Jilin Aodong National Technology Center was built into a new technology research and development center, an industry-university-research cooperation and exchange center, and a technical decision-making consulting center; in 2002, the company Approved by the Ministry of Agriculture and nine other ministries and commissions as a national key leading enterprise in agricultural industrialization; in September 2003, it was rated as an "Excellent High-tech Enterprise in the Torch Program" by the Ministry of Science and Technology; in January 2002, it was rated as a demonstration enterprise for the modern science and technology industry base of traditional Chinese medicine ;In April 2007, he won the National May 1st Labor Certificate and was once again rated as a leading enterprise in agricultural industrialization by the Ministry of Agriculture and nine other ministries and commissions; in January 2008, he was rated as a demonstration unit for enterprise informationization in Jilin Province, and won the Jilin Province A for many years Taxpayer enterprise, AAA bank credit rating, contract-abiding and credit-oriented unit, etc.; in December 2009, he won the 16th National First-Class Enterprise Management Modernization Innovation Achievements. After decades of development, the company has formed a unique brand advantage. The "Aodong and Tu" trademark was recognized as a well-known protection by the State Administration for Industry and Commerce in 1999, and has become the "China's 500 Most Valuable Brand" for six consecutive years. The company's leading products "Anshen Bu Brain Liquid", "Xuefu Zhuyu Oral Liquid", "Li Naoxin Capsules", and "Xin Nao Shutong Capsules" have maintained the titles of provincial, ministry and famous Chinese traditional Chinese medicine products for many years. "Calf spleen extract injection", "Riben nucleic acid II for injection", "Lufei granules", "Shaofu Zhuyu granules", "Yangxueyin oral liquid", "Yuxindou Capsule", "Children Chai Gui Products such as oral liquid have also been well received by the market for their stable quality and efficacy. The sales volume has increased year by year, laying a solid foundation for the company's sustainable development. The company will continue to thoroughly implement the policy of "strengthening fine production management, deepening marketing system reform, adjusting product research and development direction, promoting information network construction, improving business target assessment, and enhancing the comprehensive strength of the enterprise", create greater value for shareholders, and take into account consumption. The interests of those who are involved in the social and economic development and other related parties will contribute to the development of the society and economy.
Xiuzheng Pharmaceutical Group Co., Ltd.
Xiuzheng Pharmaceutical Health Products Co., Ltd. is a wholly-owned subsidiary of Xiuzheng Pharmaceutical Group. It mainly deals in foods and health foods mainly based on ginseng. It has more than 700 types of business and registered varieties and has 18 health food batch numbers. Since 2003, Xiuzheng Pharmaceutical Health Products Co., Ltd. has begun to explore entering the field of ginseng and antlers, and has conducted preliminary explorations with the "Xiangyangtang" ginseng and antler health chain franchise store as the main model. After 5 years of full preparation, on the premise of confirming that it already has raw material resources, channel resources and human resources, the health products company stripped off the original Xiuyangtang ginseng and antler products and established a special ginseng and antler business chain organization - correcting the standard ginseng and antlers , the standard ginseng and antlers opened a "standard ginseng and antler store" and a standard ginseng and antler counter nationwide in the form of a franchise chain, mainly engaged in the original and refined products of the "Northeast Three Treasures", supplemented by black fungus, wild vegetables, cordyceps, etc. Other special products and Chinese medicinal materials, combined with the traditional Chinese medicine health culture, are committed to providing consumers with conscientious, reliable and standard ginseng and antler products, and creating the first brand of ginseng and antler in China. At the same time, the health product company will operate high-quality products with health product qualifications in ginseng and antler products separately, and set up a fast-moving consumer goods project department, and the products will enter traditional channels such as supermarkets in the form of fast-moving consumer goods, so that ginseng and antler products can be truly close to people's lives. Currently, there are three major series of supermarket line industry, including ginseng drink series (mainly Kuyike drink), ginseng tea series (ginseng tea, American ginseng tea, etc.), ginseng honey slice series (modified soft ginseng fresh ginseng honey slices, etc.). The product has the characteristics of significant efficacy, moderate price, suitable for daily consumption, and no large-scale competition varieties, and can quickly enter the market. In order to maximize the variety advantages of the health product company, the health product company has a dedicated person to be responsible for the original large health product products, and the main channels are OTC terminals and self-built nursing hall experience stores. At present, Shuchang Oral Liquid (Moisten the Intestine and Pure Dental), Miaotai Oral Liquid (Goat Placenta Essence), Bone Yuan Bone Powder (regulating blood lipids and enhancing bone density), and Qianze Soft Capsules (Ginseng, Deer Antler, and Snow Clam are the same as The products cover high, medium and low end, fully meeting consumers' own needs and gifts. Making conscience medicine and making reassurance medicine is the consensus and strict self-requirement of the whole person. It is almost harsh and strict quality control in all aspects. We believe that good medicine comes from authentic medicinal materials. Changbai Mountain stretches for thousands of miles and breeds thousands of Chinese medicinal materials, accounting for more than 1/3 of the total amount of Chinese medicinal materials in the country. Xiuzhen Pharmaceutical relies on Changbai Mountain's natural medicinal materials library to strictly control raw materials, 22 items of raw material testing, and create original meteorological chromatography to eliminate Heavy metals and pesticide residues. Good medicine comes from innovative technology. Xiuzhen Pharmaceutical has a national-level technology center and a national-level postdoctoral workstation, with strong scientific research strength and strong technical support, and its research equipment is synchronized with Europe and the United States. Xiuzheng Pharmaceutical invests tens of millions of yuan each year for equipment renewal, and pioneering processes improve product efficacy. To enter important modernization, good medicine comes from exceeding standards. Xiuzhen Pharmaceutical strictly complies with GMP requirements and production quality control standards higher than the national standards, 77 product production modern quality inspection, and the purification level of the production workshop exceeds 100,000, which is higher than the national standards. The air is filtered through three layers, making it easier for people to disinfect up to 16 times a day. Extract 2 meals of tap water for every 10 meals, which is purer than pure water. Raw materials, technology, production and management ensure that the corrected drugs have higher quality and better efficacy, and good drugs come from correction. Revise the brand strategy as the basic strategy for corporate development, and formulate a clear brand positioning route with a forward-looking strategic perspective to ensure the efficacy of drugs, respect human needs, and reflect the value of life. Revise the industrial layout nationwide. Changchun, Beijing, Nanchang, Chengdu and other places have large-scale modern Chinese medicine research bases and industrial bases, and actively cultivate international markets to promote Chinese medicine to the world. At present, revised products are exported to Europe, America, Southeast Asia. More than 40 countries and regions including. Xiuzheng Pharmaceutical has become a leading domestic modern Chinese medicine company, and strives to become the world's top 100 pharmaceutical companies by 2030.
Xiuzheng Pharmaceutical Group Co., Ltd.
Xiuzheng Pharmaceutical Health Products Co., Ltd. is a wholly-owned subsidiary of Xiuzheng Pharmaceutical Group. It mainly deals in foods and health foods mainly based on ginseng. It has more than 700 types of business and registered varieties and has 18 health food batch numbers. Since 2003, Xiuzheng Pharmaceutical Health Products Co., Ltd. has begun to explore entering the field of ginseng and antlers, and has conducted preliminary explorations with the "Xiangyangtang" ginseng and antler health chain franchise store as the main model. After 5 years of full preparation, on the premise of confirming that it already has raw material resources, channel resources and human resources, the health products company stripped off the original Xiuyangtang ginseng and antler products and established a special ginseng and antler business chain organization - correcting the standard ginseng and antlers , the standard ginseng and antlers opened a "standard ginseng and antler store" and a standard ginseng and antler counter nationwide in the form of a franchise chain, mainly engaged in the original and refined products of the "Northeast Three Treasures", supplemented by black fungus, wild vegetables, cordyceps, etc. Other special products and Chinese medicinal materials, combined with the traditional Chinese medicine health culture, are committed to providing consumers with conscientious, reliable and standard ginseng and antler products, and creating the first brand of ginseng and antler in China. At the same time, the health product company will operate high-quality products with health product qualifications in ginseng and antler products separately, and set up a fast-moving consumer goods project department, and the products will enter traditional channels such as supermarkets in the form of fast-moving consumer goods, so that ginseng and antler products can be truly close to people's lives. Currently, there are three major series of supermarket line industry, including ginseng drink series (mainly Kuyike drink), ginseng tea series (ginseng tea, American ginseng tea, etc.), ginseng honey slice series (modified soft ginseng fresh ginseng honey slices, etc.). The product has the characteristics of significant efficacy, moderate price, suitable for daily consumption, and no large-scale competition varieties, and can quickly enter the market. In order to maximize the variety advantages of the health product company, the health product company has a dedicated person to be responsible for the original large health product products, and the main channels are OTC terminals and self-built nursing hall experience stores. At present, Shuchang Oral Liquid (Moisten the Intestine and Pure Dental), Miaotai Oral Liquid (Goat Placenta Essence), Bone Yuan Bone Powder (regulating blood lipids and enhancing bone density), and Qianze Soft Capsules (Ginseng, Deer Antler, and Snow Clam are the same as The products cover high, medium and low end, fully meeting consumers' own needs and gifts. Making conscience medicine and making reassurance medicine is the consensus and strict self-requirement of the whole person. It is almost harsh and strict quality control in all aspects. We believe that good medicine comes from authentic medicinal materials. Changbai Mountain stretches for thousands of miles and breeds thousands of Chinese medicinal materials, accounting for more than 1/3 of the total amount of Chinese medicinal materials in the country. Xiuzhen Pharmaceutical relies on Changbai Mountain's natural medicinal materials library to strictly control raw materials, 22 items of raw material testing, and create original meteorological chromatography to eliminate Heavy metals and pesticide residues. Good medicine comes from innovative technology. Xiuzhen Pharmaceutical has a national-level technology center and a national-level postdoctoral workstation, with strong scientific research strength and strong technical support, and its research equipment is synchronized with Europe and the United States. Xiuzheng Pharmaceutical invests tens of millions of yuan each year for equipment renewal, and pioneering processes improve product efficacy. To enter important modernization, good medicine comes from exceeding standards. Xiuzhen Pharmaceutical strictly complies with GMP requirements and production quality control standards higher than the national standards, 77 product production modern quality inspection, and the purification level of the production workshop exceeds 100,000, which is higher than the national standards. The air is filtered through three layers, making it easier for people to disinfect up to 16 times a day. Extract 2 meals of tap water for every 10 meals, which is purer than pure water. Raw materials, technology, production and management ensure that the corrected drugs have higher quality and better efficacy, and good drugs come from correction. Revise the brand strategy as the basic strategy for corporate development, and formulate a clear brand positioning route with a forward-looking strategic perspective to ensure the efficacy of drugs, respect human needs, and reflect the value of life. Revise the industrial layout nationwide. Changchun, Beijing, Nanchang, Chengdu and other places have large-scale modern Chinese medicine research bases and industrial bases, and actively cultivate international markets to promote Chinese medicine to the world. At present, revised products are exported to Europe, America, Southeast Asia. More than 40 countries and regions including. Xiuzheng Pharmaceutical has become a leading domestic modern Chinese medicine company, and strives to become the world's top 100 pharmaceutical companies by 2030.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Guangzhou Baiyunshan Pharmaceutical Co., Ltd. was established in 1973. In November 1992, with the approval of the Guangzhou Municipal People's Government, five other companies including Guangzhou Baiyunshan Pharmaceutical Factory were restructured and established joint-stock enterprises. In November 1993, it was listed on the Shenzhen Stock Exchange as one of the first listed companies in Guangzhou, and now has a total share capital of 469 million yuan. In 2007, the sales scale reached 3.61 billion yuan, and in 2008, the sales scale exceeded 4 billion yuan. The company has been committed to brand building for many years and is one of the first companies to establish a pharmaceutical preparation brand in China. Its brand popularity and reputation have a strong influence among consumers across the country. In 2006, the "Baiyunshan" trademark was recognized as a well-known trademark in China, and in 2007, it was identified as the title of "a famous export brand in Guangdong Province that focuses on cultivating and developing". In 2008, the brand value was evaluated as 10.52 billion yuan. In terms of network construction, the company took the lead in establishing its own marketing network across the country more than 30 years ago with the courage to be the first in the world. It has now formed a marketing network driven by its headquarters and radiated across the country and Asia and Africa. In terms of scientific and technological innovation, the company implements the "Science and Technology Baiyun Mountain" strategy, cooperates with first-class scientific research institutions, well-known domestic research institutions, and international antibiotic giants to develop drugs with world-class advanced levels. Currently, it has more than 1,700 drug approval documents, and dozens of varieties have a leading position in the national pharmaceutical industry. Among them, the development and production and launch of Xianlisu (cephalothamidine) powder injection has filled a gap in my country's self-development and development of cephalosporin antibiotics, and won the second prize of the National Technical Invention in 2007. The company established the first modern Chinese medicine research institute in South China led by Academician Liu Changxiao. The institute was approved by the state as a postdoctoral workstation; it established the "Traditional Medicine Prevention and Treatment of Viral Infectious Diseases" led by five academicians including Zhong Nanshan. This is the first cross-field industry-university-research consortium produced in my country's traditional Chinese medicine community, forming a national, provincial and municipal science and technology research and development system. The company has always adhered to the business philosophy of "love fills the world", is brave enough to assume social responsibilities, and takes care of health and dedicate love as its responsibility. Since its founding, it has always cared for the disadvantaged groups in society and pursued the cause of life and health tirelessly. Great love is shown in the face of major disasters, from the early Daxinganling fire and 98 floods to the recent SARS, the southern ice and snow disaster, the Wenchuan earthquake, etc., we actively donate money and medicine to fight the disaster; in order to inherit the culture of traditional Chinese medicine, the "Shennong Caotang" Traditional Chinese Medicine Museum was established; the company strives to build "Responsible Baiyun Mountain and Citizen Baiyun Mountain", pioneering the "family expired drug recycling mechanism", "five-level quality system", and advocating "rational use of medicines"; striving to promote energy conservation and emission reduction, environmental protection and safe production, and has won many honors such as "National Contract-Based Trust-Breaking" and Guangdong Province's "Clean Production Enterprise", "Water-saving Enterprise", "Safety Culture Demonstration Unit", and "Customer Satisfied Service Celebrity Enterprise". In the future, the company will make stability with professionalism, do a good job in scientific management, become stronger with scientific innovation, and become bigger with capital operation. Baiyunshan Pharmaceutical will build a first-class brand enterprise with high technology content, high cultural added value, high market share and strong competitiveness.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Guangzhou Baiyunshan Pharmaceutical Co., Ltd. was established in 1973. In November 1992, with the approval of the Guangzhou Municipal People's Government, five other companies including Guangzhou Baiyunshan Pharmaceutical Factory were restructured and established joint-stock enterprises. In November 1993, it was listed on the Shenzhen Stock Exchange as one of the first listed companies in Guangzhou, and now has a total share capital of 469 million yuan. In 2007, the sales scale reached 3.61 billion yuan, and in 2008, the sales scale exceeded 4 billion yuan. The company has been committed to brand building for many years and is one of the first companies to establish a pharmaceutical preparation brand in China. Its brand popularity and reputation have a strong influence among consumers across the country. In 2006, the "Baiyunshan" trademark was recognized as a well-known trademark in China, and in 2007, it was identified as the title of "a famous export brand in Guangdong Province that focuses on cultivating and developing". In 2008, the brand value was evaluated as 10.52 billion yuan. In terms of network construction, the company took the lead in establishing its own marketing network across the country more than 30 years ago with the courage to be the first in the world. It has now formed a marketing network driven by its headquarters and radiated across the country and Asia and Africa. In terms of scientific and technological innovation, the company implements the "Science and Technology Baiyun Mountain" strategy, cooperates with first-class scientific research institutions, well-known domestic research institutions, and international antibiotic giants to develop drugs with world-class advanced levels. Currently, it has more than 1,700 drug approval documents, and dozens of varieties have a leading position in the national pharmaceutical industry. Among them, the development and production and launch of Xianlisu (cephalothamidine) powder injection has filled a gap in my country's self-development and development of cephalosporin antibiotics, and won the second prize of the National Technical Invention in 2007. The company established the first modern Chinese medicine research institute in South China led by Academician Liu Changxiao. The institute was approved by the state as a postdoctoral workstation; it established the "Traditional Medicine Prevention and Treatment of Viral Infectious Diseases" led by five academicians including Zhong Nanshan. This is the first cross-field industry-university-research consortium produced in my country's traditional Chinese medicine community, forming a national, provincial and municipal science and technology research and development system. The company has always adhered to the business philosophy of "love fills the world", is brave enough to assume social responsibilities, and takes care of health and dedicate love as its responsibility. Since its founding, it has always cared for the disadvantaged groups in society and pursued the cause of life and health tirelessly. Great love is shown in the face of major disasters, from the early Daxinganling fire and 98 floods to the recent SARS, the southern ice and snow disaster, the Wenchuan earthquake, etc., we actively donate money and medicine to fight the disaster; in order to inherit the culture of traditional Chinese medicine, the "Shennong Caotang" Traditional Chinese Medicine Museum was established; the company strives to build "Responsible Baiyun Mountain and Citizen Baiyun Mountain", pioneering the "family expired drug recycling mechanism", "five-level quality system", and advocating "rational use of medicines"; striving to promote energy conservation and emission reduction, environmental protection and safe production, and has won many honors such as "National Contract-Based Trust-Breaking" and Guangdong Province's "Clean Production Enterprise", "Water-saving Enterprise", "Safety Culture Demonstration Unit", and "Customer Satisfied Service Celebrity Enterprise". In the future, the company will make stability with professionalism, do a good job in scientific management, become stronger with scientific innovation, and become bigger with capital operation. Baiyunshan Pharmaceutical will build a first-class brand enterprise with high technology content, high cultural added value, high market share and strong competitiveness.
Wenzhou Grand Machinery Technology Co., Ltd.
Wenzhou Grand Machinery Technology Co., Ltd. was established in 1999 by several experienced machinery experts, located in Wenzhou City, Zhejiang Province, China. Grand is specialized in R&D, manufacturing, exporting and providing related services of equipment in Liquid and Cream field. Main products include Bottle Liquid Filling Sealing Machine, Bag Liquid Filling Sealing Machine, Liquid Blister Filling and Sealing Machine, Tube Filling Sealing Machine, Liquid Capsule Filling Sealing Machine, Cartooning and encasing machine.
Grand has over 5,000 meters standard producing plant and modern office, with more than 85 staff consisting of efficient producing team, experienced R&D team, professional sales team and thoughtful after sale team.
Grand has passed the certification of ISO9001 and products have CE certification approved.
Grand provides reliable quality, stable performance and thoughtful after-sales service, which attracted large number of customers covering more than 160 countries, such as, China domestic, Asia, Europe, America, Mid East and Africa.
Our growth is inseparable from the trust and support of our customers. You are always welcome to our company for plant visitation, technology exchange and business cooperation.
Wenzhou Grand Machinery Technology Co., Ltd.
Wenzhou Grand Machinery Technology Co., Ltd. was established in 1999 by several experienced machinery experts, located in Wenzhou City, Zhejiang Province, China. Grand is specialized in R&D, manufacturing, exporting and providing related services of equipment in Liquid and Cream field. Main products include Bottle Liquid Filling Sealing Machine, Bag Liquid Filling Sealing Machine, Liquid Blister Filling and Sealing Machine, Tube Filling Sealing Machine, Liquid Capsule Filling Sealing Machine, Cartooning and encasing machine.
Grand has over 5,000 meters standard producing plant and modern office, with more than 85 staff consisting of efficient producing team, experienced R&D team, professional sales team and thoughtful after sale team.
Grand has passed the certification of ISO9001 and products have CE certification approved.
Grand provides reliable quality, stable performance and thoughtful after-sales service, which attracted large number of customers covering more than 160 countries, such as, China domestic, Asia, Europe, America, Mid East and Africa.
Our growth is inseparable from the trust and support of our customers. You are always welcome to our company for plant visitation, technology exchange and business cooperation.
Wuxi Zhanghua Pharmaceutical Equipment Co. Ltd
Wuxi Zhanghua Pharmaceutical Equipment Co. Ltd. was founded in 1976, committed to researching, developing and manufacturing reaction, crystallization, filtration, drying equipment. With the development of the leading technologies for 44 years, our engineering equipment is not only for the pharmaceutical industry, but also for fine chemicals, pesticides, new energy, new materials and other industries. We customize the integrated solution of reaction, crystallization, filtration and drying process equipment for clients.
Our technical team is composed of quality assurance engineers, process engineers, equipment engineers, welding engineers and electrical engineers, and most of them have working experience and engineering project experience for over ten years.
For inflammable, explosive, toxic and corrosive products in pharmaceutical, fine chemical, pesticide and new energy industries, we customize the technology and equipment solution and provide high airtight, high vacuum, fully automatic equipment for clients, to ensure safety, energy conservation and environmental protection of the production process, and compliance with EHS requirements. In addition, we will optimize technology designs for users in order to produce high quality products.
All of our equipment has met FDA and CGMP requirements, ATEX explosion-proof instruction requirements and ASME requirements, and has got PED, MD, LVD certification as well.
The equipment has been exported to several pharmaceutical and chemical enterprises in Asia and Europe, so our engineers in after-sale service department have rich experience abroad.
Wuxi Zhanghua is adhering to the spirit of professionalism, credibility, integrity, innovation and harmony, committed to becoming an advanced international company with high technology and high quality trusted by all the clients. Zhanghua has more than ten intellectual property rights, including patents, software copyright and etc., all of which helps it to keep its excellent sustainability and creativity in the industry. With years of unceasing efforts, Zhanghua has made considerable progress in reaction, crystallization, filtration and drying technology on the equipment, and has established a good image in the field of pharmaceutical and chemical industry.
Wuxi Zhanghua Pharmaceutical Equipment Co. Ltd
Wuxi Zhanghua Pharmaceutical Equipment Co. Ltd. was founded in 1976, committed to researching, developing and manufacturing reaction, crystallization, filtration, drying equipment. With the development of the leading technologies for 44 years, our engineering equipment is not only for the pharmaceutical industry, but also for fine chemicals, pesticides, new energy, new materials and other industries. We customize the integrated solution of reaction, crystallization, filtration and drying process equipment for clients.
Our technical team is composed of quality assurance engineers, process engineers, equipment engineers, welding engineers and electrical engineers, and most of them have working experience and engineering project experience for over ten years.
For inflammable, explosive, toxic and corrosive products in pharmaceutical, fine chemical, pesticide and new energy industries, we customize the technology and equipment solution and provide high airtight, high vacuum, fully automatic equipment for clients, to ensure safety, energy conservation and environmental protection of the production process, and compliance with EHS requirements. In addition, we will optimize technology designs for users in order to produce high quality products.
All of our equipment has met FDA and CGMP requirements, ATEX explosion-proof instruction requirements and ASME requirements, and has got PED, MD, LVD certification as well.
The equipment has been exported to several pharmaceutical and chemical enterprises in Asia and Europe, so our engineers in after-sale service department have rich experience abroad.
Wuxi Zhanghua is adhering to the spirit of professionalism, credibility, integrity, innovation and harmony, committed to becoming an advanced international company with high technology and high quality trusted by all the clients. Zhanghua has more than ten intellectual property rights, including patents, software copyright and etc., all of which helps it to keep its excellent sustainability and creativity in the industry. With years of unceasing efforts, Zhanghua has made considerable progress in reaction, crystallization, filtration and drying technology on the equipment, and has established a good image in the field of pharmaceutical and chemical industry.
Shanghai Marya Pharmaceutical Engineering & Project Co., Ltd
Shanghai Marya Pharmaceutical Engineering & Project Co., Ltd is a leading integrated EPC solution provider for cleanroom project, Pharmaceutical Engineering, Pharmaceutical Machinery. With decades of pharmaceutical plant design, process optimization, equipment manufacturing, site installation, and commissioning experience, we always dedicate to providing customized, ideal solutions for the pharmaceutical and medical industries.
Five Things You Should Know About Marya
1 Engineering design
Our experienced engineering team with more than 30 years experience in pharmaceutical production plants, can ensure that process and equipment for your plant is designed and manufactured in the most cost-effective manner with reliable quality to fulfil GMP/FDA/ISO/SGS requirement.
2 Manufacturing Plants
Marya's 3 manufacturing plants for clean room walls, windows, doors and pharmaceutical machinery are all under strict quality management systems certified to ISO 9001 with a focus on continuous quality improvement.
3 Installation & Commissioning
Experienced, professional, high-efficiency and strictly stick to the schedule, our installation engineers and workers team has successfully installed more than 55 projects in oversea with high customer satisfaction.
4 Proven Experience
Since 2008, Marya has helped owners in USA, UK, Russia, New Zealand, Switzerland, Italy, Malta, Poland, Iran, Israel, Bangladesh, Indonesia, Myanmar, Ecuador, Panama build their plants according to local requirements, and won a good reputation.
5 Continuous Technical Support
Whatever you buy from us, No matter when your project finished, we will provide continuous service on the operation, maintenance, repairing, spare parts supplying improving and upgrading.
Shanghai Marya Pharmaceutical Engineering & Project Co., Ltd
Shanghai Marya Pharmaceutical Engineering & Project Co., Ltd is a leading integrated EPC solution provider for cleanroom project, Pharmaceutical Engineering, Pharmaceutical Machinery. With decades of pharmaceutical plant design, process optimization, equipment manufacturing, site installation, and commissioning experience, we always dedicate to providing customized, ideal solutions for the pharmaceutical and medical industries.
Five Things You Should Know About Marya
1 Engineering design
Our experienced engineering team with more than 30 years experience in pharmaceutical production plants, can ensure that process and equipment for your plant is designed and manufactured in the most cost-effective manner with reliable quality to fulfil GMP/FDA/ISO/SGS requirement.
2 Manufacturing Plants
Marya's 3 manufacturing plants for clean room walls, windows, doors and pharmaceutical machinery are all under strict quality management systems certified to ISO 9001 with a focus on continuous quality improvement.
3 Installation & Commissioning
Experienced, professional, high-efficiency and strictly stick to the schedule, our installation engineers and workers team has successfully installed more than 55 projects in oversea with high customer satisfaction.
4 Proven Experience
Since 2008, Marya has helped owners in USA, UK, Russia, New Zealand, Switzerland, Italy, Malta, Poland, Iran, Israel, Bangladesh, Indonesia, Myanmar, Ecuador, Panama build their plants according to local requirements, and won a good reputation.
5 Continuous Technical Support
Whatever you buy from us, No matter when your project finished, we will provide continuous service on the operation, maintenance, repairing, spare parts supplying improving and upgrading.
Jiangsu Juding Environmental Protection and Energy-saving Equipment Manufacturing Co. , Ltd.
Jiangsu Juding Environmental Protection & Energy Saving Equipment Manufacturing Co., Ltd has a mature technology and complete product line, involving filtration, centrifugation, drying and crushing granulation and other products, the follow-up will be relying on its own technical strength, the introduction of more talents, and constantly develop new products, with more and better products and services to customers.
Jiangsu Juding Environmental Protection & Energy Saving Equipment Manufacturing Co., Ltd. production is efficient and durable, energy saving, the filter can be repeatedly used, safety, stability, corrosion resistance, full automation, has been successfully applied in pharmaceutical, chemical, vitamin C, glyphosate, desulfurization, environmental protection industry etc..
Jiangsu Juding Environmental Protection & Energy Saving Equipment Manufacturing Co., Ltd in line with the principle of quality first, to ensure the quality of each ex factory product, to win the credibility of quality, to win customers at the price, in good faith for development.
Jiangsu Juding Environmental Protection and Energy-saving Equipment Manufacturing Co. , Ltd.
Jiangsu Juding Environmental Protection & Energy Saving Equipment Manufacturing Co., Ltd has a mature technology and complete product line, involving filtration, centrifugation, drying and crushing granulation and other products, the follow-up will be relying on its own technical strength, the introduction of more talents, and constantly develop new products, with more and better products and services to customers.
Jiangsu Juding Environmental Protection & Energy Saving Equipment Manufacturing Co., Ltd. production is efficient and durable, energy saving, the filter can be repeatedly used, safety, stability, corrosion resistance, full automation, has been successfully applied in pharmaceutical, chemical, vitamin C, glyphosate, desulfurization, environmental protection industry etc..
Jiangsu Juding Environmental Protection & Energy Saving Equipment Manufacturing Co., Ltd in line with the principle of quality first, to ensure the quality of each ex factory product, to win the credibility of quality, to win customers at the price, in good faith for development.
Jiangyin Jirui Machinery Manufacturing Co,LTD
Jiangyin Jirui Machinery Manufacturing Co., Ltd. is located in Dongmeng Technology Zone, Nanzha Town, Jiangyin City, a flourishing city near to Shanghai in the east, close to the Yangtze River in the north and 5km away from Jiangyin Yangtze River Bridge, enjoying convenient traffic conditions. Our company takes a land area of 25,000m2 and a construction area of 15,000m2.
Our business philosophy: sincerity, innovation, harmony and efficiency. Our company centers on economic benefit, adheres to the principle of excellent return, focuses on technical innovation and system innovation, gives priority to the features of main products, and realizes professional, large-scale and group operation, so as to turn our company into a high-tech enterprise developing fast with outstanding economic and social benefits.
Professional technical talents: Our company opens itself to all talents and has a contingent of technical talents who have first-class professional level and rich practice experience. Our technical personnel are always devoted to research and development of new equipment and new technologies. Our company has become a comprehensive enterprise that mainly produces drying, mixing, sterilizing, granulating and material transferring equipment.
Advanced operation and management system: Our company adopts internationally advanced operation and management methods suited to China's actual conditions. In 2002, our company was certified to the ISO9001:2000 international quality system and established a perfect quality management system. Our products are designed in full accordance with GMP, having the comprehensive advantages of replacing imported products.
First-class products: Guided by the thoughts of high technology and new technology, our company has continuously introduced advanced technologies from abroad, and is dedicated to independent research and development of new products. Now we have 12 patented products. Among them, the EYH-series two-dimensional movement mixer, GM100 series dry heat sterilizer, vacuum vibration dryer, closed circulation dryer, injection water heat exchange water device are the typical products. The five types of products have filled domestic blanks.
Good market reputation: Our company has carried out technical exchanges and cooperation with Harbin Pharmaceutical Group, Harbin Pharmaceutical Group Design Institute, Northeast Pharmaceutical Group, Northeast General Pharmaceutical Factory Research Institute, North China Pharmaceutical Group, Xiuzheng Pharmaceutical Group and other enterprises and scientific research institutes. Our product quality is continuously improved and specifications are constantly increased. With high quality products and excellent service, our company has won recognition and praise from the above enterprises. Jiangyin Jirui Machinery has served many famous pharmaceutical plants at home and abroad. Our products are sold throughout China, and exported to Southeast Asia, Europe, Africa, etc., winning high popularity and good market reputation at home and abroad.
Jiangyin Jirui Machinery Manufacturing Co,LTD
Jiangyin Jirui Machinery Manufacturing Co., Ltd. is located in Dongmeng Technology Zone, Nanzha Town, Jiangyin City, a flourishing city near to Shanghai in the east, close to the Yangtze River in the north and 5km away from Jiangyin Yangtze River Bridge, enjoying convenient traffic conditions. Our company takes a land area of 25,000m2 and a construction area of 15,000m2.
Our business philosophy: sincerity, innovation, harmony and efficiency. Our company centers on economic benefit, adheres to the principle of excellent return, focuses on technical innovation and system innovation, gives priority to the features of main products, and realizes professional, large-scale and group operation, so as to turn our company into a high-tech enterprise developing fast with outstanding economic and social benefits.
Professional technical talents: Our company opens itself to all talents and has a contingent of technical talents who have first-class professional level and rich practice experience. Our technical personnel are always devoted to research and development of new equipment and new technologies. Our company has become a comprehensive enterprise that mainly produces drying, mixing, sterilizing, granulating and material transferring equipment.
Advanced operation and management system: Our company adopts internationally advanced operation and management methods suited to China's actual conditions. In 2002, our company was certified to the ISO9001:2000 international quality system and established a perfect quality management system. Our products are designed in full accordance with GMP, having the comprehensive advantages of replacing imported products.
First-class products: Guided by the thoughts of high technology and new technology, our company has continuously introduced advanced technologies from abroad, and is dedicated to independent research and development of new products. Now we have 12 patented products. Among them, the EYH-series two-dimensional movement mixer, GM100 series dry heat sterilizer, vacuum vibration dryer, closed circulation dryer, injection water heat exchange water device are the typical products. The five types of products have filled domestic blanks.
Good market reputation: Our company has carried out technical exchanges and cooperation with Harbin Pharmaceutical Group, Harbin Pharmaceutical Group Design Institute, Northeast Pharmaceutical Group, Northeast General Pharmaceutical Factory Research Institute, North China Pharmaceutical Group, Xiuzheng Pharmaceutical Group and other enterprises and scientific research institutes. Our product quality is continuously improved and specifications are constantly increased. With high quality products and excellent service, our company has won recognition and praise from the above enterprises. Jiangyin Jirui Machinery has served many famous pharmaceutical plants at home and abroad. Our products are sold throughout China, and exported to Southeast Asia, Europe, Africa, etc., winning high popularity and good market reputation at home and abroad.
Takeda Pharmaceutical Company Limited
Takeda is a Japanese multinational with a strong portfolio in anti-inflammatory and other therapeutic areas.
Takeda Pharmaceutical Company Limited
Takeda is a Japanese multinational with a strong portfolio in anti-inflammatory and other therapeutic areas.
Eli Lilly is a global pharmaceutical company with a focus on innovative treatments, including anti-inflammatory drugs.
Eli Lilly and Company
Eli Lilly is a global pharmaceutical company with a focus on innovative treatments, including anti-inflammatory drugs.
Teva Pharmaceutical Industries Ltd.
Teva is a global leader in generic and specialty medicines, including anti-inflammatory treatments.
Teva Pharmaceutical Industries Ltd.
Teva is a global leader in generic and specialty medicines, including anti-inflammatory treatments.
Pfizer Investment Co., Ltd.
Founded in 1849 and headquartered in New York, USA, Pfizer Inc. is a science-based, innovative, patient-first biopharmaceutical company. For more than 170 years, Pfizer has used scientific and global resources to provide treatment options for people to prolong their lives and significantly improve their quality of life. The global portfolio includes innovative medicines and vaccines. Every day, Pfizer employees all over the world are actively committed to promoting human health, promoting the prevention, treatment and curing of diseases, and actively responding to the current disease challenges and the chronic diseases of the times. In addition, Pfizer is working with health care providers, governments and communities to support and promote access to more reliable and affordable health care services for people around the world. This is consistent with Pfizer’s responsibility as a globally outstanding innovative biopharmaceutical company. In 1989, Pfizer entered the Chinese market. Currently, Pfizer's business in China covers more than 300 cities, with a total investment of more than US$1.5 billion, and has established an advanced production facility, 2 R&D centers (located in Shanghai Zhangjiang High-Tech Park and Wuhan Optical Valley respectively), Nearly 7,000 employees are distributed in business, R&D and production fields. Pfizer has launched high-quality innovative products in five major fields in China, including prescription drugs and vaccines in the fields of tumors, vaccines, anti-infection, inflammation and immunity, rare diseases, etc. The strong and complete product line is designed to meet the health needs of all stages of life.
Pfizer Investment Co., Ltd.
Founded in 1849 and headquartered in New York, USA, Pfizer Inc. is a science-based, innovative, patient-first biopharmaceutical company. For more than 170 years, Pfizer has used scientific and global resources to provide treatment options for people to prolong their lives and significantly improve their quality of life. The global portfolio includes innovative medicines and vaccines. Every day, Pfizer employees all over the world are actively committed to promoting human health, promoting the prevention, treatment and curing of diseases, and actively responding to the current disease challenges and the chronic diseases of the times. In addition, Pfizer is working with health care providers, governments and communities to support and promote access to more reliable and affordable health care services for people around the world. This is consistent with Pfizer’s responsibility as a globally outstanding innovative biopharmaceutical company. In 1989, Pfizer entered the Chinese market. Currently, Pfizer's business in China covers more than 300 cities, with a total investment of more than US$1.5 billion, and has established an advanced production facility, 2 R&D centers (located in Shanghai Zhangjiang High-Tech Park and Wuhan Optical Valley respectively), Nearly 7,000 employees are distributed in business, R&D and production fields. Pfizer has launched high-quality innovative products in five major fields in China, including prescription drugs and vaccines in the fields of tumors, vaccines, anti-infection, inflammation and immunity, rare diseases, etc. The strong and complete product line is designed to meet the health needs of all stages of life.
A biopharmaceutical company specializing in immunology, oncology, and neuroscience.
AbbVie Inc.
A biopharmaceutical company specializing in immunology, oncology, and neuroscience.
A biopharmaceutical company specializing in treatments for cancer, cardiovascular, and respiratory diseases.
AstraZeneca PLC
A biopharmaceutical company specializing in treatments for cancer, cardiovascular, and respiratory diseases.
A leader in pharmaceuticals and diagnostics, known for cancer treatments and diagnostic tools.
Roche Holding AG
A leader in pharmaceuticals and diagnostics, known for cancer treatments and diagnostic tools.
A multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
Johnson & Johnson
A multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
